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Aim: This study aimed to evaluate the possible role of heat shock protein-70 (HSP70) induction by
17-allylaminodemethoxygeldanamycin (17-AAG) in collagen-induced arthritis in rats. Material and methods:
Male Wistar rats were divided into five groups (n = 10/group) and were treated intraperitoneally twice a week for 4
weeks, namely normal control (saline), arthritis control (AR; saline), AR + 17-AAG, AR +methotrexate (MTX),
and AR + 17-AAG +MTX. At the end of the treatments, arthritic score was determined and then the animals were
sacrificed. Erythrocyte sedimentation rate (ESR), serum levels of HSP70, interleukin-17 (IL-17), tumor necrosis
factor-alpha (TNF-α), rheumatic factor (RF), C-reactive protein (CRP), malondialdehyde (MDA), glutathione
peroxidase (GPx), and matrix metalloproteinase-9 (MMP-9) were determined. Results: In the AR group, all
parameters increased significantly, except for GPx, which showed a pronounced decrease. The 17-AAG and/or
MTX treatments significantly reduced arthritic score, ESR, IL-17, TNF-α, RF, CRP, MDA, and MMP-9
with significant increase in GPx compared to the AR group. The HSP70 level was significantly higher in the
AR + 17-AAG and the AR + 17-AAG +MTX groups but significantly lower in the AR +MTX group as
compared to the AR group. Also, it was significantly lower in the AR +MTX group as compared to the AR +
17-AAG group. Conclusion:We concluded that HSP70 induction by 17-AAG attenuated the inflammatory process
in a rheumatoid arthritis (RA) model induced by collagen, which suggested that HSP70 inducers can be promising
agents in the treatment of RA.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune systemic disease with chronic inflammatory
character that results in morbidity and mortality. It affects joints including cartilages, synovial
membranes, and bone, resulting in bone erosion and cartilage degeneration with subsequent
loss of functions of joints (10). Its etiology is poorly understood (16). Collagen-induced
arthritis (CIA) is commonly used in experimental studies as it resembles RA in humans.
CIA can be induced by injection of type-II collagen with subsequent development of severe
polyarthritis in animals (11).
Methotrexate (MTX) is considered a standard antirheumatic drug due to its effectiveness
in prolonged clinical use. Mechanisms of action of MTX might be explained by its anti-
inflammatory, cytostatic, immunosuppressive, and antiapoptotic effects (22, 34). In addition,
MTX inhibits dihydrofolate reductase enzyme that is involved in purine synthesis, with
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subsequent inhibition of de-novo synthesis of pyrimidine and purine (18). However, its
administration is limited due to its toxic adverse effects as it can cause serious infections,
cytopenia, ulceration of mucous membranes, and nausea (3). Hence, there is a need to use
new antirheumatic drugs or develop a new strategy in the treatment of RA in combination
with MTX.
Heat shock proteins (HSPs) constitute a chaperone-conserved protein family that
plays important roles in refolding of protein misfolding under normal and stress condi-
tions. The HSP70 is one of these HSPs induced from the cells in response to stress
conditions, such as oxidative stress, infections, inflammation, exposure to heat stress, and
ischemia-reperfusion (15). The HSP70 is also found in the bloodstream in patients who
suffer from inflammatory or autoimmune diseases such as RA (39). It was proved to have
a major role in suppressing autoimmune responses in some experimental models (4). The
administration of HSP70 itself or HSP70-derived peptides has been reported in a few
studies as a therapy for arthritis, both in vitro using cells of patients with RA or in animal
models (56, 63).
The 17-allylaminodemethoxygeldanamycin (17-AAG) is a HSP70 co-inducer (17). It is
a geldanamycin analog, which has antitumor effects via induction of apoptosis (59). Its
mechanism of action might be due to its binding to heat shock protein-90 (HSP90), hence
preventing conformational folding mediated by HSP90 and enhancing oncoprotein degrada-
tion; furthermore, it inhibits the binding of HSP90 with heat shock factor-1, with subsequent
transcription of chaperones HSP70 (21).
The 17-AAG has favorable safety pharmacological use in experimental models, since
previous studies showed that 17-AAG has lesser hepatotoxic effects than geldanamycin
(6, 21, 30, 61), suggesting that the toxic effects may be avoided by applying small doses. The
17-AAG has also been used in the treatment of cancer in numerous experimental models (53).
In addition, it has been proved that 17-AAG attenuated inflammation in models of brain
injury (30) and other non-neurological experimental models of diseases, such as lung injury
(8), uveitis (50), and atherosclerosis (27).
To our knowledge, there is no previous study evaluating the effect of 17-AAG in RA.
Thus, this work proposed to examine the possible role of HSP70 induction by 17-AAG in
CIA in rats. Furthermore, some hypotheses about its action and potential effects were
investigated.
Materials and Methods
Animals
This study was conducted on 50 male Wistar rats. They were 10–12 weeks old, weighing
190–230 g. They were obtained from the animal house of Tanta University of Medical
Sciences. The animals were housed in clean cages (90 cm length× 62 cm width), five rats per
cage, at suitable temperature (23± 2 °C) with 12-h light–dark cycle. The animals were allowed
free access to food and water. The experimental protocol was approved by the ethical
committee of the Faculty of Medicine, Tanta University (code approval number: 4320/04/30).
Drug and chemicals
Type-II collagen, incomplete Freund’s adjuvant (IFA), and 17-AAG were obtained
from Sigma Aldrich Co. (St. Louis, MO, USA). MTX was purchased from the United Co.
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(Cairo, Egypt) for distribution. Both 17-AAG and MTX were dissolved in saline. All kits that
were used for measuring the studied parameters were obtained from Bio-Diagnostic Co.
(Giza, Egypt).
Experimental design
The animals in all the experimental groups received all treatments intraperitoneally twice a
week from the first day of the experiment for 4 weeks. They were randomly divided into
five groups (10 rats per each group) as following:
1. Normal control group: rats received saline as a vehicle.
2. Arthritis control (AR) group: rats received saline as a vehicle. Arthritis was induced as
described later.
3. Arthritis group treated with 17-AAG (AR + 17-AAG): rats received 17-AAG in a dose
of 5 mg/kg (21).
4. Arthritis group treated with MTX (AR +MTX): rats received MTX in a dose of
0.4 mg/kg (45).
5. Arthritis group treated with combination of 17-AAG and MTX (AR + 17-AAG +
MTX): rats received 17-AAG in a dose of 5 mg/kg and MTX in a low dose of
0.2 mg/kg (33).
Induction of arthritis
Arthritis was induced in the rats according to the method of Karatas et al. (26) as following:
the rats were anesthetized by phenobarbital sodium (15 mg/kg intraperitoneally) (44). Type-II
collagen was dissolved in 0.01 M acetic acid (1 mg/ml) and was emulsified in IFA at a 1:1
ratio. Then, they were injected intradermally into the tail in a dose of (100 μg/rat) and back
paws in a dose of (50 μg in each paw). After 1 week from the first injection of collagen, rats
were injected again (100 μg/rat) into the tail. The onset of arthritis occurred after about 13–14
days from the first injection of collagen. Arthritis was confirmed when the arthritis score
became more than 1.
Arthritic score
The arthritis could be assessed by a macroscopic scoring for the four limbs. The score was
ranged from 0 to 4 as described previously (7), as following:
Score 0=No swelling of the joints.
Score 1= Swelling and/or erythema of one joint.
Score 2= Swelling and/or erythema of two joints.
Score 3= Swelling and/or erythema of three joints.
Score 4= Severe arthritis throughout the entire paw.
The affected joints might be included (interphalangeal, metacarpophalangeal, and
radiocarpal joints) in forepaws and (interphalangeal, metatarsophalangeal, and tibiotarsal
joints) in hind paws.
The severity of arthritis score for each animal was calculated by summing the individual
paw scores (max: 16).
Blood sampling and biochemical assay
At the end of the experiment, after 4 weeks, the animals were sacrificed by cervical
decapitation and blood samples were collected. Part of the fresh blood samples was used
for determination of erythrocyte sedimentation rate (ESR) according to the method of Plebani
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and Piva (48). The rest of the blood was centrifuged at 3,000 cycles for 10 min. The serum
samples were separated and stored at −80 °C for biochemical analysis of HSP70 using a
quantitative enzyme-linked immunosorbent assay (ELISA) technique. The intra- and inter-
assay coefficient of variation ranged between 4.5% and 7% (40). Interleukin-17 (IL-17) (1)
and tumor necrosis factor-alpha (TNF-α) were determined (49). In addition, rheumatic factor
(RF) (42), C-reactive protein (CRP) (12), malondialdehyde (MDA) (5), glutathione peroxi-
dase (GPx) (5), and matrix metalloproteinase-9 (MMP-9) (25) were determined using
commercial ELISA kits. The procedures for all biochemical assays were performed as
described in the product manuals. The results were estimated from the standard calibration
curves on the internal standards.
Statistical analysis
The data were shown as mean± standard deviation. Data from the study were analyzed using
one-way analysis of variance followed by Tukey’s test to assess the significance. The
p values <0.05 were considered statistically significant. All the analyses were performed
using SPSS for Windows (version 21.0; Chicago, IL, USA).
Results
Arthritis score
As shown in Fig. 1, arthritis was developed in the AR group as proved by high arthritic
scores. As compared to the AR group, the arthritis score was significantly decreased in all
AR-treated groups.
HSP70, IL-17, and TNF-α
These were presented in Fig. 1. Compared to the control group, the serum level of HSP70 was
significantly increased in the AR and all AR-treated groups. It was significantly higher in the
AR + 17-AAG and the AR + 17-AAG +MTX groups but significantly lower in the AR+
MTX group as compared to the AR group. In addition, it was significantly lower in the AR+
MTX group as compared to the AR+ 17-AAG group.
Regarding the serum levels of pro-inflammatory cytokines IL-17 and TNF-α, they were
significantly higher in the AR group as compared to the normal control group. Whereas in the
AR-treated groups, the serum levels of these pro-inflammatory cytokines were significantly
decreased as compared to the AR group. However, their levels were still significantly higher
in all AR-treated groups as compared to the normal control, except for the level of IL-17 in
the AR + 17-AAG+MTX group that returned to the normal value as compared to the normal
control group.
ESR, RF, and CRP
As presented in Fig. 2, ESR, RF, and CRP were significantly increased in the AR group as
compared to the normal control group. It was noticed that, as compared to the AR group, all
these parameters were significantly decreased in the AR-treated groups. However, their levels
were still significantly higher as compared to the normal control group.
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Fig. 1. Arthritis score,
HSP70, IL-17, and
TNF-α in all studied
groups. Data are
given as mean± SD.
ap< 0.05 vs. control
group, bp< 0.05 vs.
AR group, cp< 0.05
vs. AR+ 17-AAG
group, dp< 0.05 vs.
AR+MTX group
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MDA, GPx, and MMP-9
SerumMDA andMMP-9 levels were significantly increased in the AR group with concomitant
decrease in serum GPx level as compared to the normal control group (Fig. 3). In contrast, the
MDA and MMP-9 levels were significantly decreased with concomitant increase in GPx level
in the AR-treated groups compared to the AR group. The levels of GPx returned to normal
control levels in the AR+MTX and the AR+ 17-AAG+MTX groups (Fig. 3).
Fig. 2. ESR, RF, and CRP in all studied groups. Data are given as mean± SD. ap< 0.05 vs. control group,
bp< 0.05 vs. AR group, cp< 0.05 vs. AR+ 17-AAG group, dp< 0.05 vs. AR+MTX group
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Discussion
This study revealed that HSP70 induction by 17-AAG attenuated the inflammatory condi-
tions of RA induced by collagen injection. The results showed that the arthritic score and
several inflammatory parameters increased significantly in the AR group, which were blunted
by treatments with either 17-AAG and/or MTX. Furthermore, the serum level of HSP70 was
Fig. 3. MDA, GPx, and MMP-9 in all studied groups. Data are given as mean± SD. ap< 0.05 vs. control group,
bp< 0.05 vs. AR group, cp< 0.05 vs. AR+ 17-AAG group, dp< 0.05 vs. AR+MTX group
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significantly higher in the AR group as compared to the normal control group, and in the
17-AAG-treated groups compared to the other groups. In agreement with our results,
Najafizadeh et al. (39) proved that HSP70 increased in patients with RA and it was correlated
with the activity of RA. However, our results suggest that HSP70 induction by 17-AAG
might be beneficial in the improvement of the inflammatory state in this arthritis model.
The IL-17, a cytokine synthesized by T-helper cells called Th-17 cells (64), contributes
to the inflammatory process in the pathogenesis of RA, and its plasma level increases during
the course of RA (35). It could stimulate the production of pro-inflammatory cytokines such
as TNF-α, IL-1, chemokines, and receptor activation of nuclear factor κB (NF-κB) ligand
(RANKL) protein in the synovial fluid. The IL-17 activates the macrophages and chon-
drocytes, which synthesize the destructive enzymes promoting erosion and destruction of
joints (65). It also stimulates the release of destructive enzymes from the fibroblasts in the
synovium (38). It has been reported that IL-17 activates the osteoclasts with subsequent bone
resorption, in addition to production of nitric oxide and prostaglandin E2 that have been
involved in destruction of cartilages (43). Thus, IL-17 injection in the joints of normal rats
caused damage in joints (38). In this study, 17-AAG, MTX, and their combination
significantly reduced serum IL-17 levels. In agreement with earlier results, MTX treatment
reduced levels of IL-17 in RA (19, 36).
The reduction in the levels of IL-17 by 17-AAG might be due to induction of HSP70.
This was in agreement with a previous study, which showed that HSP90 blockade was
associated with HSP70 upregulation with subsequent inhibition of NF-κB (60). The later is
one of the major factors stimulating the proliferation of Th-17 cells, hence increasing IL-17
expression (2, 41). However, a research found that HSP70 expression in the cellular stress
responses was associated with increased IL-17 expression (20). This was in agreement with
results of this work, as in the AR group, both HSP70 and IL-17 levels were significantly
elevated. Tissue damage and the elevated cytokine levels cause the release of HSP70 (62).
TNF-α is another pro-inflammatory mediator that has an important role in the patho-
genesis of inflammatory diseases of the joints as well. Previous results have proved that drugs
that inhibit TNF-α attenuate the inflammatory conditions (10). In this study, the levels of
TNF-α increased in the AR group. This is in accordance with previous studies (10, 45), as the
treatment with 17-AAG and/or MTX significantly reduced the serum level of TNF-α, which
suggested the anti-inflammatory effects of both drugs. In an in vitro study, HSP70 prevented
the increase of the inflammatory cytokines induced by lipopolysaccharide (14). Furthermore,
in an experimental stroke model in rats, overexpression of HSP70 inhibited the production of
TNF-α (29).
In agreement with other previous results (32, 47, 54), this study showed that serum
levels of ESR, RF, and CRP were significantly increased in the AR group. It was noticed that
these parameters were significantly lowered by 17-AAG and/or MTX treatments.
It has been hypothesized that the rise of CRP levels might be due to the activation of
macrophages, B and T lymphocytes, and the production of the inflammatory cytokines such
as IL-6 and TNF-α that lead to the oxidative damage of vital organs such as the liver, with
subsequent production of inflammatory mediators such as CRP (57). Also, TNF-α promotes
the production of CRP in the liver via NF-κBwith a subsequent rise in CRP level in the serum
(9, 45), and CRP leads to activation of RANKL protein, which causes bone and joint
destructions (28). It was demonstrated that 17-AAG has inhibited NF-κB nuclear transloca-
tion in the brain (51). Therefore, its anti-arthritic effects in this study could be due to the
inhibition of NF-κB pathway with subsequent suppression of the production of the
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inflammatory mediators. Moreover, previous studies suggested that MTX inhibited NF-κB
with subsequent abrogation of the inflammatory process in an RA model (58).
In this study, MDA level was significantly increased with concomitant significant
decrease in GPx level in the AR group. These results are in accordance with previous studies
in RA patients, which demonstrated high levels of MDA in the serum and synovial fluids with
decreased antioxidant enzymes such as GPx (52).
Oxidative stress has been proved to play an important role in the pathogenesis of RA.
Reactive oxygen radicals (e.g., hydrogen peroxide) produced by the inflammatory cells of the
synovial fluid cause damage of the joints (23). Free radicals lead to damage of DNA structure,
proteins, and lipids with subsequent lipid peroxidation (46). MDA is a product of lipid
peroxidation; hence, it has been increased in RA diseases (13). The antioxidant enzymes,
such as GPx, play an important role against free radicals (24), and the activity of this enzyme
has been decreased in RA diseases (37).
The results of this study demonstrated that the serum level of MDA was significantly
decreased with significant increase in GPx level by 17-AAG and/or MTX treatment, which
suggested that both drugs have antioxidant effects.
Finally, the results of this study showed that the serum level of MMP-9 was significantly
increased in AR as compared to the normal control. The treatment with 17-AAG and/or MTX
significantly attenuated the increase in this enzyme. MMPs are enzymes that play a critical
role in bone and cartilage destruction. It was suggested to be produced by macrophages. The
IL-17 increased the production of MMP-9 from these cells (31). Also, 17-AAG reduced
MMP-9 levels, which could be explained by inhibiting NF-κB signaling pathway (51).
In our experiment, the treatments started simultaneously as the arthritis was induced and
continued about 2 weeks after the onset of arthritis. Therefore, the role of 17-AAG was
suggested not only to be preventive but also therapeutic. Some previous studies started the
treatments of RA during induction of arthritis (45, 55). Therefore, it is a limitation in this
study that it could have been supplemented with experimental groups in which treatment
would have been started after the onset of arthritis. Hence, this is recommended for further
research.
Conclusions
We demonstrated that 17-AAG alone or in combination with a low dose of MTX attenuated
the RA in CIA model by its anti-inflammatory and antioxidant effects, which might be due
to the induction of HSP70. Therefore, we suggest that HSP70 co-inducers may be
promising agents in the treatment of RA, or its combination with a low dose of MTX
may have a therapeutic effect in the treatment of RA. However, further histopathological,
behavioral, and molecular biological studies are required to reveal the effects of HSP70
inducers as therapeutic agents in RA on bone and cartilages of the joints and their
mechanisms of actions.
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